Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V.

Abstract excerpt

PURPOSE: KRAS mutations are present in approximately 40-45% of colorectal cancers (CRC), but currently approved KRAS-directed therapies address only the small G12C subset. G12D and G12V account for a much larger proportion of KRAS-mutant CRC and remain major unmet therapeutic targets. This review summarizes emerging strategies for non-G12C KRAS-mutant CRC. METHODS: Current preclinical, translational, and early...

Topics

• Humans
• Colorectal Neoplasms
• Mutation
• Proto-Oncogene Proteins p21(ras)
• Molecular Targeted Therapy
• Antineoplastic Agents